decisionhealth Newsletters, Part B News - 2004 Issue 12 (December)
Drug prices: Cuts to cancer drug prices not so bad after all, claims Government Account-ability Office
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a Government Accountability Office review of Medicare payment changes affecting cancer and anti-nausea drugs, along with related oncology drug administration payments and projected savings under the Medicare Modernization Act. It is relevant to oncology practices, coding/billing staff, and reimbursement analysts who track federal payment policy and its effects on patient access, practice revenue, and beneficiary copays.
Why This Topic Matters
The piece highlights how federal drug payment policy changes may affect oncology reimbursement, practice operations, and Medicare beneficiary costs.
What You Will Learn
- What the article says about Medicare payment changes for oncology drugs
- How the Government Accountability Office is presented in relation to these payment updates
- What broad reimbursement and beneficiary cost impacts are discussed
- Why oncology practices are watching these policy changes
Who Should Read This
- Oncology coders
- Medical billers
- Practice administrators
- Reimbursement analysts
- Oncologists
- Health policy readers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com